Latest news with #Lawrenceville
Yahoo
5 days ago
- Yahoo
Man wanted for sexual battery in Lawrenceville: authorities issue warning
The Brief Edwin Darnell Windham-Slater is wanted for a sexual battery offense committed on June 1 in Lawrenceville and remains at large. Windham-Slater has other active felony warrants and a history of sexually related offenses. Authorities urge the public to report sightings to Detective Osterberg or Crime Stoppers, and warn not to approach him but to call 911. LAWRENCEVILLE, Ga. - Authorities in Lawrenceville are asking for the public's help in locating a man wanted in connection with a recent sexual battery case. What we know According to the Lawrenceville Police Department, Edwin Darnell Windham-Slater is accused of approaching a woman and committing a sexual battery offense on June 1 within the city. Police said Windham-Slater fled the scene and remains at large. In addition to the sexual battery charge, Windham-Slater has other active felony warrants unrelated to the incident. Investigators also noted he has a history of sexually related offenses. What they're saying Anyone with information on Windham-Slater's whereabouts is urged to contact Detective Osterberg at EOsterberg@ or call 770-670-5174. Tips can also be submitted anonymously to Crime Stoppers Greater Atlanta at 404-577-TIPS (8477). Police warn the public not to approach Windham-Slater if he is seen and to call 911 immediately. The Source The Lawrenceville Police Department provided the details for this article.
CBS News
03-06-2025
- General
- CBS News
One person killed in Lawrenceville shooting
One person has died after a shooting in Pittsburgh's Lawrenceville neighborhood. Police were called to Butler and 50th Street just around 3:45 p.m. for reports of two individuals involved in an altercation at the Sunoco gas station. Arriving officers found the victim on the ground near a vehicle, and they were pronounced deceased on the scene by medical personnel. A lone suspect remained on the scene and called 911 to report the incident. He was detained by police and taken into custody for questioning. The names of the victim or suspect haven't been released.
Yahoo
24-05-2025
- Yahoo
Georgia twins deaths ruled a double suicide, here's what happened
The Georgia Bureau of Investigation (GBI) announced on Wednesday that the deaths of 19-year-old twins, found fatally shot atop Bell Mountain on March 8, have been ruled a double suicide. Qaadir Malik Lewis and Naazir Rahim Lewis, from Lawrenceville, were discovered by hikers near the North Carolina border, a location their family described as unfamiliar to them, according to NBC News. Initially, the event was assumed to be an apparent murder-suicide, but this week the ruling has changed and the investigation is to close in the coming weeks. They planned to visit friends in Boston on March 7, but only Naazir went to the airport. He did not board his flight and returned home. Cellular location data tracked the twins' movements from their home to Bell Mountain. Video evidence shows the brothers alone at the mountain summit. Forensic evidence indicates the twins fired the weapon used, with records showing Naazir purchased ammunition on March 5. The GBI investigation concluded that the deaths were a joint act of suicide. However, the family remains uncertain about the circumstances leading to the tragic event. Saying that they were looking to hire a private investigator specializing in homicide to look into the brothers' deaths, the family organized a GoFundMe page for the twins. Vanessa Countryman is the Trending Topics Reporter for the the Deep South Connect Team Georgia. Email her at Vcountryman@ This article originally appeared on Athens Banner-Herald: Twin brothers deaths ruled double suicide
Yahoo
24-05-2025
- Yahoo
Georgia twins deaths ruled a double suicide, here's what happened
The Georgia Bureau of Investigation (GBI) announced on Wednesday that the deaths of 19-year-old twins, found fatally shot atop Bell Mountain on March 8, have been ruled a double suicide. Qaadir Malik Lewis and Naazir Rahim Lewis, from Lawrenceville, were discovered by hikers near the North Carolina border, a location their family described as unfamiliar to them, according to NBC News. Initially, the event was assumed to be an apparent murder-suicide, but this week the ruling has changed and the investigation is to close in the coming weeks. They planned to visit friends in Boston on March 7, but only Naazir went to the airport. He did not board his flight and returned home. Cellular location data tracked the twins' movements from their home to Bell Mountain. Video evidence shows the brothers alone at the mountain summit. Forensic evidence indicates the twins fired the weapon used, with records showing Naazir purchased ammunition on March 5. The GBI investigation concluded that the deaths were a joint act of suicide. However, the family remains uncertain about the circumstances leading to the tragic event. Saying that they were looking to hire a private investigator specializing in homicide to look into the brothers' deaths, the family organized a GoFundMe page for the twins. Vanessa Countryman is the Trending Topics Reporter for the the Deep South Connect Team Georgia. Email her at Vcountryman@ This article originally appeared on Athens Banner-Herald: Twin brothers deaths ruled double suicide
Associated Press
24-05-2025
- Business
- Associated Press
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants LAWRENCEVILLE, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 7,222,223 shares of its common stock (or pre-funded warrants in lieu therof) and short-term warrants to purchase up to an aggregate of 14,444,446 shares of common stock at a purchase price of $0.45 per share (or pre-funded warrant in lieu thereof) and accompanying short-term warrants in a private placement priced at-the-market under Nasdaq rules. The warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock upon exercise of the warrants at an exercise price of $0.45 per share and will expire three years from the date of stockholder approval. The offering is expected to close on or about May 27, 2025, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the the exclusive placement agent for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, is acting as financial advisor. The aggregate gross proceeds to the Company from the private placement is expected to be approximately $3.25 million, before deducting placement agent fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the short-term warrants, if fully-exercised on a cash basis, will be approximately $6.5 million. No assurance can be given that any of such short-term warrants will be exercised. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The shares of common stock, pre-funded warrants and short-term warrants described above were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the 'Act') and Regulation D promulgated thereunder and, along with the shares of common stock underlying the pre-funded warrants and short-term warrants, have not been registered under the Act or applicable state securities laws. Accordingly, the shares of common stock, the pre-funded warrants, the short-term warrants and the shares of common stock underlying the pre-funded warrants and short-term warrants may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ('SEC') or an applicable exemption from such registration requirements. The securities were offered only to accredited investors. Pursuant to a registration rights agreement, the Company has agreed to file one or more registration statements with the SEC covering the resale of the shares of common stock and the shares issuable upon exercise of the pre-funded warrants and short-term warrants. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About IMUNON IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company's lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit Forward-Looking StatementsContacts:
